Welcome to our dedicated page for Kraig Biocraft Laboratories In news (Ticker: KBLB), a resource for investors and traders seeking the latest updates and insights on Kraig Biocraft Laboratories In stock.
Kraig Biocraft Laboratories (KBLB) pioneers advanced biomaterials through genetic engineering of recombinant spider silk. This dedicated news hub provides investors and industry stakeholders with essential updates on the company's scientific progress and strategic initiatives.
Access timely announcements covering production milestones, research breakthroughs, and partnership developments. Our curated collection includes press releases on genetic enhancements, scalable manufacturing achievements, and applications in technical textiles, medical devices, and defense materials.
Discover updates on proprietary silk protein innovations, including hybrid fibers combining spider and caddisfly DNA sequences. Track progress in commercializing sustainable alternatives to conventional materials through verified operational expansions and quality control advancements.
Bookmark this page for streamlined access to KBLB's official communications. Regularly updated content ensures informed decision-making about this biotechnology innovator's role in transforming material science markets.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced its preparation for a response to the U.S. Air Force under the Defense Production Act Investments program. This initiative aims to bolster U.S. bio-industrial manufacturing capabilities, specifically targeting materials like spider silk. Kraig Labs is set to submit its detailed response by April 19, 2023. While this does not guarantee funding or a proposal request, it signifies the growing interest in biomanufactured materials. COO Jon Rice expressed optimism about Kraig's role in enhancing domestic biomanufacturing and updating the DoD on its advancements.
Kraig Biocraft Laboratories (OTCQB: KBLB) has announced the creation of two senior-level genetic engineering positions within its research and development team in the U.S. This expansion aims to enhance the team's capabilities, accelerating the development of spider silk technologies. The company expects these new roles will significantly increase research throughput, allowing for faster transition from concept to production for various spider silk protein designs. COO Jon Rice emphasized the potential for advancing new materials and transgenics in this exciting phase for the company.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) announced the delivery of the first two hybrid-cross Dragon Silk™ strains to its production partner in Vietnam. This development addresses key challenges in large-scale production, enhancing the robustness of silkworms. The new strains combine the mechanical performance of Dragon Silk with local silkworm traits, increasing cocoon size and resilience. Kraig Labs is also pursuing a four-line hybrid-cross program to further improve yields. COO Jon Rice highlighted the progress in overcoming production scaling challenges, signaling potential increases in production capacity and efficiency.
Kraig Biocraft Laboratories (KBLB) announced the near completion of an $8 million convertible debenture with Yorkville Advisors, converting over 98% of this debt into equity. The company reports over $4.5 million in liquid assets, with only $150,000 remaining debt to Yorkville. The funds have been invested in expanding production facilities in Vietnam and enhancing R&D capabilities in the U.S. Kraig Labs aims to scale up spider silk production and develop innovative technologies, with a focus on strategic partnerships to meet market demand.
Kraig Biocraft Laboratories (OTCQB: KBLB) has engaged textile expert Jeff Dorton to enhance the development of innovative yarns and fabrics using Dragon Silk™. This partnership aims to revolutionize the textile industry, specifically through the launch of Spydasilk Enterprises in Singapore, the company's joint venture. Dorton brings extensive experience from brands like The North Face, focusing on sustainability and high-performance materials. The collaboration is expected to create several new textile applications, expanding Kraig Labs' market presence in luxury and performance textiles.
Kraig Biocraft Laboratories (KBLB) has been granted a business license to operate in Lam Dong Province, Vietnam, enhancing its efforts in spider silk production. This expansion leverages the region's ideal climate for silkworm rearing and existing silk production infrastructure. Notably, the Lam Dong Agro-Forestry Research Experiment Center is instrumental in boosting mulberry yields, which Kraig Labs has started utilizing, showing a doubled production capacity. The company maintains its headquarters in Quang Nam, where it produces proprietary silkworm eggs. COO Jon Rice expressed optimism about the integration of their technology into Vietnamese silk production.
Kraig Biocraft Laboratories (KBLB) has released a new video showcasing its recombinant spider silk production operations, providing insights into its U.S. R&D and Vietnam quality control labs. The video emphasizes the work of its dedicated researchers in creating cost-effective and eco-friendly spider silk products. COO Jon Rice highlighted the team's efforts in developing advanced materials. Future videos will explore breeding operations and the team behind these innovations.